print logo

Geriatric Medicine Development - Carving out New Opportunities to Treat Age-related Diseases: Radiant Insights

Geriatric Medicine Development Market, Geriatric Medicine Development Market Research, Geriatric Medicine Development Market Report, Geriatric Medicin
Michelle Thoras | 12.11.2015

More than 50% of prescriptions is written for people aged 65 years and older. Many older people suffer from comorbid conditions and one in three takes at least five drugs or more on a daily basis. This significantly increases the risk of Adverse Drug Events (ADEs) and hospitalization. Up to one third of emergency admissions in elderly people is drug-related.

There remains a lack of clinical data to support prescription decisions as relatively few medicines have been clinically evaluated in age-appropriate patients. In addition, many drugs are not available in formulations that are suitable for the elderly, leading to non-compliance and lack of therapeutic efficacy. In 2011, the EMA introduced its Geriatric Medicines Strategy to ensure that the medical requirements of older people are identified earlier in the drug development process. In 2012, the ICH E7 guidelines were revised to include a greater focus on involving more geriatric patients in drug trials.

For complete report, visit @ http://www.radiantinsights.com/research/geriatric-medicine-development-carving-out-new-opportunities-to-treat-age-related-diseases

Scope


Reviews the current regulatory landscape and helps sponsors to understand the potential impact of recent guidelines.
Assesses the barriers to entry in geriatric medicines and identifies potential ways to overcome them and improve clinical decision making.
Evaluates the importance of establishing Target Quality Product Profiles (TQPP) to help sponsors determine the target patient population earlier on in drug development.
Identifies treatment gaps and commercial opportunities based on primary care real-time data and KOL insights.
Analyses different strategies to develop age-appropriate medicines in niche therapeutic fields and discusses methods to encourage the smarter prescription of medicines.

For more reports of this category, click here: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare

Key Reasons to Purchase


Utilize the insights from this study to analyze the barriers facing the geriatrics market
Understand the impact of drug development in this market now and in the future
Find out why regulators are paying more attention to unnecessary "exclusion criteria" and encouraging the inclusion of older people to ensure trials are age-appropriate and more representative of the real world setting.
Assess the opportunities available for companies to develop age-appropriate dosages and formulations for existing drug classes that are currently widely associated with ADEs in the elderly as well as new therapeutic prospects.

About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. It assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information, Visit: http://www.radiantinsights.com/

Media Contact:

Company Name: Radiant Insights, Inc
Contact Person: Michelle Thoras
Email: sales@radiantinsights.com
Phone: (415) 349-0054
Address: 28 2nd Street, Suite 3036
City: San Francisco
State: California
Country: United States
Blog: http://rimarketresearchandreports.blogspot.in/